Chun-Ling Dai
Overview
Explore the profile of Chun-Ling Dai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song Y, Dai C, Shinohara M, Tung Y, Zhou S, Huang W, et al.
Brain Behav Immun
. 2024 Aug;
122:185-201.
PMID: 39142420
Amyloid-β (Aβ) and hyperphosphorylated tau protein are targets for Alzheimer's Disease (AD) immunotherapies, which are generally focused on single epitopes within Aβ or tau. However, due to the complexity of...
2.
Basurto-Islas G, Tung Y, Dai C, Iqbal K, Gong C
J Alzheimers Dis Rep
. 2024 May;
8(1):615-626.
PMID: 38746631
Background: Diabetes mellitus (DM) increases the risk for cognitive impairment and Alzheimer's disease (AD). Diabetic ketoacidosis (DKA), a serious complication of DM, may also cause brain damage and further AD,...
3.
Chadman K, Adayev T, Udayan A, Ahmed R, Dai C, Goodman J, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833432
Background Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and autism. Gene therapy may offer an efficient method to ameliorate the symptoms of this disorder....
4.
Li L, Miao J, Jiang Y, Dai C, Iqbal K, Liu F, et al.
Exp Neurol
. 2023 Jan;
362:114337.
PMID: 36717015
Tau pathology is essential in the pathogenesis of Alzheimer's disease (AD) and related tauopathies. Tau immunotherapy aimed at reducing the progression of tau pathology provides a potential therapeutic strategy for...
5.
Dai C, Liu F, Iqbal K, Gong C
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499564
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that eventually leads to dementia and death of the patient. Currently, no effective treatment is available that can slow or halt the...
6.
Li L, Miao J, Chu D, Jin N, Tung Y, Dai C, et al.
CNS Neurosci Ther
. 2022 Sep;
28(12):2245-2259.
PMID: 36114722
Introduction: Neurofibrillary tangle (NFT) of hyperphosphorylated tau is a hallmark of Alzheimer's disease (AD) and related tauopathies. Tau lesion starts in the trans-entorhinal cortex, from where it spreads to limbic...
7.
Hu W, Dai C, Niu J, Iqbal K
J Alzheimers Dis Rep
. 2022 Jun;
6(1):245-255.
PMID: 35719714
Background: The triple transgenic mouse model of Alzheimer's disease (3×Tg-AD) has gained popularity in Alzheimer's research owing to the progressive development of both amyloid- and tau pathologies in its brain....
8.
Peng S, Gu J, Dai C, Iqbal K, Liu F, Gong C
Mol Biol Rep
. 2022 Mar;
49(5):3955-3964.
PMID: 35235160
Purpose: Cellular responses following cerebral ischemia/reperfusion injury are critical to recovery and survival after ischemic stroke. Understanding of these cellular responses can help the design of therapies to protect brain...
9.
Gong C, Dai C, Liu F, Iqbal K
Front Aging Neurosci
. 2022 Feb;
14:837649.
PMID: 35222001
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that eventually leads to dementia and death of the patient. Despite the enormous amounts of resources and efforts for AD drug development...
10.
Wei W, Liu Y, Dai C, Baazaoui N, Tung Y, Liu F, et al.
J Alzheimers Dis
. 2021 May;
82(2):631-646.
PMID: 34057082
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impairments in synaptic plasticity and cognitive performance. Cognitive dysfunction and loss of neuronal plasticity are known to begin decades...